Information Provided By:
Fly News Breaks for May 24, 2016
LJPC
May 24, 2016 | 08:40 EDT
Lake Street analyst Carl Byrnes started La Jolla Pharmaceutical with a Buy rating and $25 price target. The analyst expects positive topline date readout of the ATHOS-3 trial by year-end 2016. He believes LJPC-501 is "uniquely positioned as a breakthrough therapy for catecholamine-resistant hypotension.'
News For LJPC From the Last 2 Days
There are no results for your query LJPC